Yeah I saw the Evaluatepharma article and it was surprisingly incorrect factually. They probably would not have been so dismissive had it been a US analyst covering the stock.
They were not comparing apples to apples. They talked about a deal value estimated by Bell Potter for a worldwide license vs. the actual value NEU obtained for just US license, saying Bell Potter set expectations too high..
Once NEU ultimately licenses out Ex-US rights, the Acadia deal value plus the Ex-US deal value may still be close to or higher than what Bell Potter was estimating in 2018.
ACADIA TALKS TROFINETIDE, page-84
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.80 |
Change
0.300(1.54%) |
Mkt cap ! $2.528B | |||
| Open | High | Low | Value | Volume |
| $19.49 | $19.92 | $19.25 | $5.352M | 271.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $19.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.80 | 516 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.80 |
Change
0.300 ( 0.98 %) |
||||
| Open | High | Low | Volume | ||
| $19.41 | $19.92 | $19.25 | 77870 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| NEU (ASX) Chart |
